title: Imaging studies in drug development: Parkinson's disease.
abstract: Positron emission tomography (PET) and single photon emission computed tomography (SPECT) can help confirm the diagnosis of parkinsonian disorders where this is in doubt and provide potential biomarkers for following the effects of putative neuroprotective and restorative agents on disease progression. PET can also establish that novel therapeutics reach their intended targets and generate dose-occupancy profiles. Finally, PET and SPECT can indirectly monitor changes in brain dopamine levels and so throw light on the pharmacology underlying treatment-associated complications.:
authors: MRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College London, Cyclotron Building, Hammersmith Hospital, Du Cane Rd, London, UK W12 0NN. Electronic address:david.brooks@csc.mrc.ac.uk.
authors: David J
authors: DJ
authors: Brooks